Mohammed VI chaired in the province of Benslimane the launching ceremony for a manufacturing plant for Covid-19 and other vaccines in a bid to reach self-sufficiency and help supply vaccines to African nations.
The Benslimane project consists of setting up a plant for the manufacture and syringing of vaccines (anti-Covid and other vaccines), with 3 industrial lines whose combined production capacity will reach 116 million units in 2024.
These lines will be dedicated to the production of pre-filled syringes, liquid vials, and lyophilized vials.
The projected investment is approximately €200 million, and the start of production of the trial batches is scheduled for July 30, 2022.
The project, which is the result of a public-private partnership, including the support of one of the world leaders in biotechnology and the “Fill & Finish” industry, the Swedish company Recipharm, will ensure the Kingdom’s self-sufficiency in vaccines and make the country a leading biotechnology platform on the African continent and the world in the field of the “fill & finish” industry.
Named “SENSYO Pharmatech”, the industrial unit, the largest platform by the capacity of Fill & Finish of vaccines in Africa, will eventually become one of the first 5 in the world. This large-scale project aims, in the medium term (2022-2025), to transfer the aseptic filling and active substance manufacturing of more than 20 vaccines and bio-therapeutic products, including 3 anti-Covid-19 vaccines, to Morocco in less than 3 years, covering more than 70% of the Kingdom’s needs and more than 60% of those of the Continent.
It is planned in this framework the transfer to Morocco of advanced biotechnology platforms, including clinical research, development, and production of cell and gene therapies, stem cells, and advanced in vitro diagnostic technologies.
The project aims, in the long term (2023-2030), the creation of an African Pole of biopharmaceutical and vaccine innovation in Morocco recognized worldwide and this, within the framework of a partnership between major international players in the fields of research and development of advanced technologies in vaccines and bio-therapeutic products and all Moroccan institutions of supervision, including the Ministry of Higher Education, the Ministry of Health, the Ministry of the Interior, the Ministry of Industry and Finance.
A massive and continuous transfer of know-how is planned to position the Kingdom in the next 5 years as the continent’s locomotive in research, development and production of advanced biopharmaceutical products.
Morocco produces more than 3 million doses locally per month. Production capacity will increase to about 5 million doses starting in February 2022 and to more than 20 million doses per month by the end of 2022. By 2025, Morocco will be able to produce more than 2 billion doses of vaccine.
add your comment
Terms of publication : Not to offend the writer, people, sacred things, or attack religions or the divine self, and refrain from racist incitement and insults.